Welcome to our dedicated page for SRX Health Solutions SEC filings (Ticker: SRXH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SRx Health Solutions, Inc. (NYSE American: SRXH) files a range of SEC documents that together outline its evolving strategy, capital structure and planned combination with EMJ Crypto Technologies Inc. (EMJX). On this page, investors can review current reports on Form 8-K, registration statements on Form S-1 and S-1/A, and other filings that describe material agreements, financing transactions and listing-status developments.
In its 8-K filings, the company discloses the Share Exchange and Asset Transfer Agreement to acquire EMJX, CCC Crypto Corp. and related intellectual property assets, including technology that uses artificial intelligence to predict outcomes from data sets. These reports also cover stockholder approvals for a future name change to EMJX, Inc. and a planned ticker change to EMJX, amendments to the Certificate of Incorporation to increase authorized common shares, and the designation of Series A Convertible Preferred Stock with detailed rights and conversion terms.
SRXH’s registration statements on Form S-1 and S-1/A provide additional information on private placements of Series A Convertible Preferred Stock and warrants, as well as an equity line of credit arrangement with Keystone Capital Partners, LLC. These documents explain how the company may raise capital through the issuance of equity and equity-linked securities, and they discuss risks associated with ownership of its securities. Filings also address NYSE American continued listing standards, including notices of non-compliance related to stockholders’ equity and the exchange’s acceptance of the company’s plan to regain compliance.
Through Stock Titan, users can access these filings as they are made available on EDGAR and review them alongside AI-generated summaries that highlight key terms, structural features and risk considerations. This includes simplified explanations of complex documents such as 8-Ks describing material definitive agreements, S-1 registration statements detailing resale registrations and capital-raising arrangements, and governance-related amendments to the company’s charter and bylaws.
SRx Health Solutions, Inc. reported a NYSE American noncompliance notice tied to Section 1003(a)(ii), which requires stockholders’ equity of at least $4 million when a company has losses in three of its four most recent fiscal years. The notice, dated October 14, 2025, has no immediate effect on the listing, and SRXH common stock will continue trading on NYSE American.
The company must submit a compliance plan by November 13, 2025, detailing actions to regain compliance by July 14, 2026. Under Section 1009 procedures, delisting proceedings could be initiated if the deficiency is not cured, and the exchange may accelerate action if trading levels are viewed as abnormally low. SRx stated it is developing plans and remains in discussions with the exchange. A press release was issued on October 17, 2025.
SRx Health Solutions, Inc. disclosed that its board will seek shareholder approval for an Additional Reverse Split of its common stock to occur after the previously approved reverse split from July 23, 2025. The Additional Reverse Split would be set at a ratio anywhere in the 15-to-1 to 85-to-1 range, with the Board to select the final ratio and timing so long as it occurs no later than March 31, 2026. The filing also references an issuance threshold equal to 19.99% of the common stock then outstanding in connection with an ELOC Purchase Agreement or related securities convertible into or exercisable for common stock. The Board retains discretion over the precise split ratio within the approved range following stockholder approval.
SRx Health Solutions, Inc. provided a preliminary information statement describing current beneficial ownership and the potential effects of an Additional Reverse Split on trading liquidity and continued listing on the NYSE American. The filing lists individual holdings for named executives and directors: Lionel F. Conacher 1,096,883 shares (4.30%), Simon Conway 204,792 shares (0.80%), David White 344,975 shares (1.35%), Kent Cunningham 410,596 shares (1.61%), and Carolina Martinez 356,963 shares (1.40%). All executive officers and directors as a group (7 persons) hold 8,515,075 shares (33.40%). A reported 5% shareholder, Glenn Gibbons, holds 2,880,157 shares (11.30%). The document also shows total outstanding share counts in the range of approximately 4.997B–4.999B shares across presented scenarios. The company highlights that an Additional Reverse Split could affect liquidity, prevailing trading price, market capitalization, and the Company’s ability to maintain its NYSE American listing.
David Allan White, a newly appointed director of SRx Health Solutions, Inc. (SRXH), reported multiple stock acquisitions tied to his appointment. The Form 4 shows acquisitions on 04/24/2025, 05/01/2025, and 08/25/2025 totaling 344,975 shares held after the latest transaction and a separate block of 6,200 shares held directly. Prices per share for the reported purchases were $2.09, $1.23, and $0.40 respectively. The filing also reports 69,732 common stock purchase warrants exercisable on 07/07/2025 with a $0.62 exercise price expiring on 07/07/2028. The filer notes the reported shares reflect holdings as of his appointment as director on 04/24/2025.
SRx Health Solutions, Inc. reported that its Board of Directors appointed Joshua A. Epstein as a director effective October 1, 2025. He will serve until a successor is elected and qualified or until his resignation or removal.
Epstein brings over 20 years of operational, advisory, investing, and legal experience across energy, technology, healthcare, medical cannabis, blockchain, and gaming sectors. His background includes leadership roles in corporate development, private equity, cannabinoid and wellness manufacturing, and international medical cannabis, as well as earlier work as an M&A and securities attorney.
The condensed consolidated 10-Q shows SRx Health Solutions incurred a net loss of $15.1 million for the three months and $29.7 million for the nine months ended June 30, 2025, compared with losses of $3.1 million and $11.1 million in the prior-year periods. The company reports a working capital deficiency of $49.6 million and $67.7 million (two comparative periods), material impairments to customer-list intangibles, and goodwill-related adjustments tied to prior acquisitions.
Significant corporate actions include a reverse acquisition that made SRx Canada the accounting acquirer, a private placement raising $8.8 million (1,280,000 shares and 2,756,697 pre-funded warrants), issuance of shares for advisory and settlement purposes, repurchase activity (76,800 shares repurchased in the period) and the subsequent filing for creditor protection under CCAA by the Canadian operating subsidiary, which led to a write-off of a prepaid amount. The company also has convertible and secured notes outstanding and a senior secured convertible note financing referenced as a subsequent event.
SRx Health Solutions, Inc. filed an 8-K announcing it has dismissed CBIZ CPAs P.C. as its independent registered public accounting firm and engaged Davidson and Company LLP for the fiscal year ending September 30, 2025. The change was approved by the Board of Directors based on the Audit Committee’s recommendation.
The filing reviews prior audit opinions, noting that both Better Choice Company, Inc. and SRx Health Solutions (Canada), Inc. previously received going concern explanatory paragraphs and had multiple material weaknesses in internal control over financial reporting, including revenue recognition, IT and general control deficiencies.
While preparing the June 30, 2025 Form 10-Q, the company identified an error that overstated revenue by approximately $1.8 million for the fiscal year ended September 30, 2024; management concluded the error was not material and will revise, rather than restate, those financial statements and expects an additional material weakness related to revenue recognition. The filing also states that SRx Canada is under Companies’ Creditors Arrangement Act protection in Canada and that most of its assets have been sold through court-approved transactions.
SRx Health Solutions, Inc. filed an 8-K announcing it has dismissed CBIZ CPAs P.C. as its independent registered public accounting firm and engaged Davidson and Company LLP for the fiscal year ending September 30, 2025. The change was approved by the Board of Directors based on the Audit Committee’s recommendation.
The filing reviews prior audit opinions, noting that both Better Choice Company, Inc. and SRx Health Solutions (Canada), Inc. previously received going concern explanatory paragraphs and had multiple material weaknesses in internal control over financial reporting, including revenue recognition, IT and general control deficiencies.
While preparing the June 30, 2025 Form 10-Q, the company identified an error that overstated revenue by approximately $1.8 million for the fiscal year ended September 30, 2024; management concluded the error was not material and will revise, rather than restate, those financial statements and expects an additional material weakness related to revenue recognition. The filing also states that SRx Canada is under Companies’ Creditors Arrangement Act protection in Canada and that most of its assets have been sold through court-approved transactions.
The DEF 14C excerpt for SRX Health Solutions, Inc. lists beneficial ownership figures and share reserve counts without broader narrative or proposals. It names individual holders including Glen Gibbons (1,280,926 shares, 3.85%), Michael Young (362,047 shares, 1.09%), Lionel F. Conacher (325,831 shares, 0.98%), Simon Conway (50,664 shares, 0.15%), David White (190,847 shares, 0.57%), Kent Cunningham (179,403 shares, 0.54%), and Carolina Martinez (125,770 shares, 0.37%). The document shows 33,198,807 outstanding common shares and reports shares reserved for options/warrants (3,160,808), future equity awards (5,878,981), and conversion of convertible notes (61,998). It also lists large totals of authorized but unissued common shares (e.g., 157,699,406 and higher figures in alternate columns). The excerpt identifies the disclosure scope to include directors, proposed nominees, officers, and their affiliates.
SRx Health Solutions, Inc. notified the SEC that it could not timely file its quarterly report for the period ended June 30, 2025 because it requires additional time to finalize the financial statements to be included in that report. The company checked Rule 12b-25(b), indicating the subject report will be filed on or before the fifteenth calendar day following the prescribed due date. The firm disclosed it completed a reverse merger in April 2025 and expects the upcoming earnings statements to reflect a significant change in results of operations versus the prior-year period due to that transaction and certain non-recurring charges and developments affecting legacy operations. The filing names Carolina Martinez as the contact with telephone 813-599-7956 and indicates all other required periodic reports for the prior 12 months have been filed.
SRx Health Solutions, Inc. announced that, pursuant to a Settlement, Share Forfeiture and Mutual Release Agreement, certain founders and officers of its wholly-owned subsidiary SRx Canada forfeited for cancellation approximately 18,839,332 million shares of SRx Canada stock that were exchangeable one-for-one into the Company's common stock. In consideration the Company agreed to release those parties from certain claims, and the filing states the forfeited shares represent approximately 60% of the aggregate number of Common Stock and Exchangeable Shares outstanding immediately prior to the Settlement.
The Company also accepted the voluntary resignation of director Adesh Vora, effective August 13, 2025, citing SRx Canada’s previously announced proceedings in Canada under the federal Companies' Creditors Arrangement Act. The Settlement Agreement is filed as Exhibit 10.1 and a related press release as Exhibit 99.1.